Prior to SARS-CoV-2 vaccination rollout, natural infections rates for SARS-CoV-2 were extremely low in the Canadian population. With the implementation of the SARS-CoV-2 vaccines in late 2020 and early 2021, Canadians had varying levels of humoral protection against Wild type and variant of concern (VOC) SARS-CoV-2. By late 2021 and early 2022 almost all Canadian blood donors had evidence of either vaccination or natural infection. These serological profiles would be further complicated by increasing evidence of breakthrough infections in this population March 2022. Given the diversity of patterns of humoral responses in Canadians, this session will have two objectives.

1. Review seroprevalence levels in Canada and the emerging evidence on the minimum antibody threshold required to confer protection against COVID-19

2. Discuss whether SARS-CoV-2 antibody tests are clinically useful